PharmaJet, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2005-06-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.pharmajet.com
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
Phase 2
Not yet recruiting
- Conditions
- Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy VolunteersSARS CoV-2
- Interventions
- Biological: COMIRNATY®
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06919796
- Locations
- 🇺🇸
Hope Clinic of the Emory Vaccine Center Division of Infectious Diseases, Department of Medicine, School of Medicine, Decatur, Georgia, United States
Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System
Phase 2
Withdrawn
- Conditions
- Vaccine Reaction
- Interventions
- Device: PharmaJet Tropis® Needle-Free Injection SystemDevice: PharmaJet Stratis® Needle-Free Injection System
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- PharmaJet, Inc.
- Registration Number
- NCT06142461
- Locations
- 🇮🇩
Universitas Padjadjaran, Bandung, Indonesia
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
Phase 1
Active, not recruiting
- Conditions
- Vaccine Reaction
- Interventions
- Device: PharmaJet Tropis Needle-free Injection SystemDevice: PharmaJet Stratis Needle-free Injection System
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT06002503
- Locations
- 🇺🇸
Velocity Clinical Research, Cincinnati, Ohio, United States
Inactivated Influenza Via Jet Injection
Phase 4
Completed
- Conditions
- Influenza, Human
- Interventions
- Biological: Influenza Vaccine
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 985
- Registration Number
- NCT02290691
- Locations
- 🇺🇸
Optimal Research, LLC, Rockville, Maryland, United States
🇺🇸Optimal Reserach, LLC, Mishawaka, Indiana, United States
🇺🇸Optimal Research LLC, Huntsville, Alabama, United States
Jet Injection for Influenza
Phase 4
Completed
- Conditions
- Influenza, Human
- Interventions
- Biological: AFLURIA vaccine (2012-2013 formulation)Device: Needle-SyringeDevice: Stratis needle-free injection device
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 1250
- Registration Number
- NCT01688921
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸University of Colorado Health Harmony Campus, Fort Collins, Colorado, United States
🇺🇸Medical Center of the Rockies, Loveland, Colorado, United States
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
Phase 4
Completed
- Conditions
- Influenza Prophylaxis
- Interventions
- Device: Needle and SyringeDevice: Stratis Jet InjectorBiological: 2011-2012 Fluzone trivalent inactivated influenza vaccine
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- PharmaJet, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT01644149
- Locations
- 🇺🇸
Bel-Rea Institute, Denver, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath